NEW YORK (GenomeWeb News) – Synthetic biology firm Intrexon said late Wednesday that it has closed a Series F preferred investment round that raised $150 million.

Proceeds from the financing round will be used for working capital to establish additional channel collaborations in the firm's core sectors, including healthcare, food, energy, and environment, it said, adding that funding will also be used for further development of its technology platforms and expansion of its sales and marketing and R&D efforts.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.